Abstract:Objective: This study explored the value of circulating tumor cells (CTC) detected by chromosome 8 centromere probe in diagnosis of non-small cell lung cancer (NSCLC) as well as correlation between CTC counts and clinical pathological characteristics. Methods: We collected 136 patients with newly diagnosed NSCLC (101 males and 35 females, age ranged from 34 to 79 years), 149 patients with non-malignant pulmonary diseases (103 males and 46 females, age ranged from 24 to 80 years) and 32 healthy volunteers (5 males and 27 females, age ranged from 24 to 42 years). Detection was performed using an epithelial cell adhesion molecule-independent strategy that combined immunocytochemistry staining (ICC) of CD(45) and fluorescence in situ hybridization detection (FISH) with chromosome 8 centromere probe (CEP8). CTC was defined as 4',6-diamidino-2-phenylindole (DAPI) positive, CD(45) negative and CEP8 more than 2 positive points. Quantitative data were reported as x±s and Mann Whitney test was used to compare them. Measurement data were analyzed as contingency tables and Pearson chi-squared test was used. P values of less than 0.05 were considered statistically significant. Results: CTCs were detected in 114 patients (83.8%) with NSCLC, 35 patients (23.5%) with non-malignant pulmonary diseases (P<0.000 1) and 5 volunteers (15.6%). CTC counts in NSCLC patients were (5.98±0.64) per 3.2 ml and (0.60±0.13) per 3.2 ml (P<0.000 1). A receiver operating characteristic curve (ROC) analysis showed similar capability of CTC count, with CEA, in discriminating NSCLC and non-malignant diseases with an area under ROC curve of 0.854 (95% confidence interval: 0.808-0.900, P<0.001). Cutoff of 2 circulating tumor cells per 3.2 ml peripheral blood gave the highest Youden Index of 0.614 in diagnosis of NSCLC with sensitivity of 72.1% (98/136) and specificity of 89.3% (133/149). When patients with CTC≥2/3.2 ml peripheral blood or serum CEA≥5 ng/ml were considered as having NSCLC, sensitivity and specificity of this combined test were 87.5% (119/136) and 85.9% (128/149), with a higher Youden Index of 0.734. No correlation was observed between positive rate of CTC (rate of patients with CTC≥2/3.2 ml peripheral blood) and age, gender, smoking status, pathologic types, and clinical stages. Conclusions: CTC counts detected by CD(45)-FISH is higher in NSCLC patients than in non-malignant disease patients. CTC≥2/3.2 ml peripheral blood is valuable in discriminating NSCLC from nonmalignant diseases, which can be more accurate when combined with CEA.

[Diagnosis Value of the Detection of CYFRA21-1 in Non-Small Cell Lung Cancer].

Study on the correlationship between CK19mRNA and CyFRA21-1 in peripheral blood of lung cancer patients

CYFRA21-1 Tests in the Diagnosis of Non-Small Cell Lung Cancer: A Meta-Analysis.

Prognostic Value of Serum Cytokeratin 19 Fragments (cyfra 21-1) in Patients with Non-Small Cell Lung Cancer.

The Diagnostic and Prognostic Significance on Detection of Cyfra 21-1 in Head and Neck Squamous Cell Carcinoma Patients

CYFRA 21-1 as a tool for distant metastasis detection in lung cancer

Application Value of CYFRA21-1 Combined with NSE, CEA, and SCC-Ag in Lung Cancer.

CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels

[The Value of Circulating Tumor Cells Detected by Chromosome Centromere Probe Identification in Diagnosis of Non-Small Cell Lung Cancer].

Serum CYFRA21-1 As an Effective Tumor Biomarker for Patients with Nasopharyngeal Carcinoma

The Value of Circulating CYFRA21-1 Expression in Patients with Nasopharyngeal Carcinoma: a Study of 529 Subjects

Clinical values of serum cytokeratin-19 fragment in nasopharyngeal carcinoma

The Diagnostic and Prognostic Value of the Combination of Tumor M2-Pyruvate Kinase, Carcinoembryonic Antigen, and Cytokeratin 19 Fragment in Non-Small Cell Lung Cancer

Clinical significance of tumor marker ProGRP,NSE,CYFRA21-1 in lung cancer

B-360 Usefulness of the Ratios of CYFRA21-1 and P53 Autoantibody Immune Complexes to Their Free Antigens in Lung Cancer

Serum CYFRA 21-1 as a Prognostic Marker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

Diagnostic value analysis of combined detection of Trx, CYFRA21-1 and SCCA in lung cancer

Detection of CYFRA 21-1 in human serum by an electrochemical immunosensor based on UiO-66-NH 2 @CMWCNTs and CS@AuNPs

Quantification of the lung cancer tumor marker CYFRA 21-1 using protein precipitation, immunoaffinity bottom-up LC-MS/MS

Systematic Review of CYFRA 21-1 As a Prognostic Indicator and Its Predictive Correlation with Clinicopathological Features in Non-small Cell Lung Cancer: A Meta-Analysis

Value of Serum CK19-2G2,CYFRA 21-1 and CA-125 Detecting in Lung Cancer Diagnosis